Epithelial–mesenchymal plasticity (EMP) enables cells to interconvert between several
states across the epithelial–mesenchymal landscape, thereby acquiring hybrid epithelial …

Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and
account for nearly all cancer-related deaths. Both metastasis and therapy resistance are …

Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose
their characteristics and acquire mesenchymal traits to promote cell movement. This …

Epithelial mesenchymal transition (EMT) is a complex process through which epithelial (E)
cells lose their adherens junctions, transform into mesenchymal (M) cells and attain motility …

Metastasis is the leading cause of mortality among cancer patients. Dissemination enabled
by an epithelial-to-mesenchymal transition (EMT) of carcinoma cells has long been …

Tumor cells demonstrate substantial plasticity in their genotypic and phenotypic
characteristics. Epithelial-mesenchymal plasticity (EMP) can be characterized into dynamic …

In prostate cancer (PCa), similar to many other cancers, distant organ metastasis symbolizes
the beginning of the end disease, which eventually leads to cancer death. Many …

Stem cell characteristics have been associated with treatment resistance and poor
prognosis across many cancer types. The ability to induce and regulate the pathways that …

Cancer stem cells (CSCs) in prostate cancer (CaP) are regarded as major contributors to
radioresistance due to complex mechanisms including enhanced DNA repair, increased …

The increasing incidence of resistance to chemotherapeutic agents has become a major
issue in the treatment of oral cancer (OC). Epithelial-mesenchymal transition (EMT) has …